Elite Pharmaceuticals Inc (ELTP)

[imanjen13]

The quarter ending 6/20/23 should show flat to small decline of revenue compared to 2022 results of 7.7 M total.

Two statistics to watch will be the expense for R&D and the cash on hand,which will show a significant decline as the company paid off the $11M loan.

Nasrat should indicate in the conference call that the company expects to receive word in the near future that the FDA has accepted the complete application for Oxycontin.

For investors, the $64 question will be the progress Kikov is making with the distribution network, the expended increase in revenue from current and new products as well as FDA and DEA interest in increasing Elite's quota as one of the major distributors of the Adderall drugs.